NEW YORK – Vision Medicals has received the CE-IVD mark for its SARS-CoV-2 Clinical Sequencing assay, which uses next-generation sequencing.
The test is built on a proprietary metagenomic sequencing assay that runs on an Illumina NextSeq sequencer. Each kit contains 36 tests and is able to detect SARS-CoV-2 at a sensitivity of 500 copies per milliliter. With the CE mark in hand, Vision Medicals plans to focus on the European market.